Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opioid Abuse-Deterrent Labeling Claim Decision By FDA Could Come Soon

Apr 15 2013

• By Cathy Dombrowski

Related Content

FDA’s Opioid To-Do List Could Redefine Pain Market For Brands, Generics

Feb 18 2013

Citizen Petition Seeks Limited Opioid Drug Indication To Curb Overuse And Abuse

Aug 06 2012

No Abuse-Resistance Claim For Endo’s Opana ER Reformulation

Dec 12 2011

Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market

Jun 20 2011

Tamper-Resistance Could Allow New Opioid Formulations To Differentiate Themselves

Nov 01 2010

Related Companies

Purdue Pharma L.P.

Endo, Inc.

Pfizer Inc.

Additional Topics

United States Regulation BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window